BIOLASE, Inc. (NASDAQ:BIOL) Q1 2024 Earnings Call Transcript
Operator: Good day, and welcome to the BIOLASE First Quarter 2024 Results Conference Call. All participants will be in a listen-only mode.
Biolase Inc (BIOL)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Millennium Management Israel Englander | 0 | $0 | -100% | 0% |
| 2. | Citadel Investment Group Ken Griffin | 0 | $0 | -100% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.61 | 1,307,931 | 10,936,444 | 2020-02-11 | Filing | ||
| $0.45 | 70,000 | Officer, Director | 621,530 | 2021-11-30 | Filing | |
| $0.61 | 35,000 | Officer, Director | 551,530 | 2021-08-20 | Filing | |
| $0.75 | 40,000 | Officer, Director | 516,530 | 2021-05-19 | Filing | |
| $57.50 | 1,843 | Large Shareholder | 1,843 | 2019-10-29 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.28 | 187,774 | 5,522,223 | 2020-12-18 | Filing | ||
| $0.28 | 572,671 | 5,709,997 | 2020-12-17 | Filing | ||
| $0.28 | 90,575 | 6,282,668 | 2020-12-16 | Filing | ||
| $0.30 | 1,200,000 | 6,373,243 | 2020-12-04 | Filing | ||
| $0.30 | 1,115,000 | 7,573,243 | 2020-11-30 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 25,018 | $28,070 | 0% | |
| 2. | 19,060 | $21,385 | 0.01% | |
| 3. | 13,770 | $15,450 | 0% | |
| 4. | 10,911 | $12,242 | 0% | |
| 5. | 10,726 | $12,035 | 0% |
News See All
BIOLASE, Inc. (NASDAQ:BIOL) Q4 2023 Earnings Call Transcript
Operator: Good afternoon and welcome to the BIOLASE Fourth Quarter and Full Year 2023 Results Conference Call. All participants will be in listen-only mode.
BIOLASE, Inc. (NASDAQ:BIOL) Q4 2023 Earnings Call Transcript
BIOLASE, Inc. beats earnings expectations. Reported EPS is $-1.76, expectations were $-2.56.
BIOLASE, Inc. (NASDAQ:BIOL) Q2 2023 Earnings Call Transcript
Operator: Good day, and welcome to the BIOLASE Second Quarter 2023 Financial Results Conference Call. Please note this call is being recorded.
BIOLASE, Inc. (NASDAQ:BIOL) Q1 2023 Earnings Call Transcript
Operator: Good day, and welcome to the BIOLASE First quarter 2023 Financial Results Conference Call. Please note this call is being recorded.
BIOLASE, Inc. (NASDAQ:BIOL) Q4 2022 Earnings Call Transcript
Operator: Greetings. Welcome to the BIOLASE 2022 Fourth Quarter and Full Year Financial Results Call. Please note, this conference is being recorded.
Biolase Inc (BIOL): Hedge Funds In Wait-and-See Mode
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns.
10 Best Dental Stocks to Buy Now
Dental health is one of the key indicators for overall health and well being. However, it is evident that the industry has been one of the most overlooked in the healthcare sector today.
Do Hedge Funds Love Biolase Inc (BIOL)?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Hedge Fund and Insider Trading News: Stanley Druckenmiller, David Tepper, Constellation Pharmaceuticals Inc (CNST), BIOLASE Inc (BIOL), Novocure Ltd (NVCR), and a Lot More
The recovery in the oil industry is attracting some of the most recognized billionaires in money management.